MFDS recommends restricted usage of Hanmi’s Olita Tab for terminal cancer patients

Published: 2016-10-06 13:29:47

Updated: 2016-10-06 14:13:13

The Ministry of Food and Drug Safety(MFDS) recommended restricted usage of the Hanmi Pharm’s non-small cell lung cancer therapy ‘Olita Tab,’ which had a death patient during clinical trials, for terminal cancer patients, instead of taking extreme measures, such as revocation of approval.

The MFDS’s Central Drug Deliberation Committee held a meeting on the 4^th, and advised the Ministry of Fo...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.